Insider Selling: Omeros (NASDAQ:OMER) CAO Sells 5,000 Shares of Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total transaction of $84,750.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $84,750. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Performance

Shares of Omeros stock traded up $0.17 during trading hours on Monday, hitting $17.36. The company’s stock had a trading volume of 2,466,385 shares, compared to its average volume of 2,290,120. The firm has a fifty day moving average of $11.04 and a 200-day moving average of $11.58. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $18.14. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of 13.56 and a beta of 2.54.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, sell-side analysts expect that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OMER. Acadian Asset Management LLC purchased a new stake in shares of Omeros in the 1st quarter valued at approximately $357,000. XTX Topco Ltd acquired a new position in shares of Omeros during the second quarter worth $191,000. Invesco Ltd. grew its stake in shares of Omeros by 34.1% during the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 29,644 shares in the last quarter. Marshall Wace LLP increased its holdings in Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 97,224 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Omeros in the second quarter valued at $40,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

OMER has been the subject of several recent research reports. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday. D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, April 21st. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.